Kairos Pharma Ltd. (NYSE American: KAPA) reported positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to two months for those receiving apalutamide alone (P=0.0008). This result is important because it suggests that adding ENV-105 to standard androgen deprivation therapy could substantially delay disease progression in a patient population with limited treatment options.
The magnitude of the benefit—nearly 16 additional months of progression-free survival—is clinically meaningful. If confirmed in the completed trial, this combination could become a new standard of care for mCRPC, potentially improving outcomes for thousands of patients. The data also validate Kairos Pharma's approach of targeting CD105, a protein implicated in drug resistance and disease relapse. By reversing resistance mechanisms, ENV-105 may restore sensitivity to existing therapies, addressing a major unmet need in oncology.
In response to the interim findings, Kairos Pharma has modified the Phase 2 protocol to enroll patients earlier in disease progression. Specifically, patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. This amendment is designed to expand the eligible patient population and facilitate enrollment. The company now targets completion of the Phase 2 trial in or before the fourth quarter of 2027.
The strategic shift to earlier intervention aligns with the hypothesis that targeting CD105 may be more effective before resistance mechanisms are fully established. By moving ENV-105 into earlier lines of therapy, Kairos Pharma hopes to demonstrate even greater clinical benefit and potentially accelerate the path to regulatory approval. The interim data and protocol amendment have implications beyond this trial: they could shape future clinical development strategies for ENV-105 across other cancer types where CD105 plays a role.
For investors, the announcement represents a significant de-risking event. The statistically significant PFS benefit provides proof of concept for ENV-105 and supports the company's structural biology platform. With a clear clinical milestone ahead, Kairos Pharma is positioned to attract additional interest from partners and the investment community. The company's newsroom, available at https://ibn.fm/KAPA, provides ongoing updates.
BioMedWire, a specialized communications platform focused on biotechnology and life sciences, disseminated the announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers solutions including InvestorWire for wire distribution, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, visit BioMedWire.
